Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House
The 2017 user fee reauthorization bill contains provisions that should be significantly easier for the agency to implement compared with the 2012 measure. Senate clears clean bill for president's review.
You may also be interested in...
Proponent says companies ready to use new expanded access pathway that US FDA will have essentially no involvement in.
Commissioner Gottlieb’s recent remarks on pending federal 'Right-to-Try' legislation were his most positive to date; he pushed back on earlier versions that would have removed FDA from process.
Generic labels can't easily be changed if reference product is withdrawn, meaning legislative fix is needed to add current recommendations to outdated labels.